Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance

Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance

Background: Evolocumab is a humanized immunoglobulin G2 monoclonal antibody, directed against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), prescribed in hypercholesterolemic patients. The safety profile of this drug is currently defined by the data of pre-authorization clinical trials. The...

Full description

Bibliographic Details
Main Authors: Fabrizio Calapai, Carmen Mannucci, Mariaconcetta Currò, Luigi Cardia, Emanuela Esposito, Gioacchino Calapai, Ilaria Ammendolia
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Pharmaceuticals
Subjects:
evolocumab
adverse reactions
pharmacovigilance
PCSK9 inhibitors
EudraVigilance
Online Access:https://www.mdpi.com/1424-8247/17/3/364

Internet

https://www.mdpi.com/1424-8247/17/3/364

Similar Items